AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Rare Disease (Alexion) — US product sales by Year
Rare Disease (Alexion) — US product sales ($M) ($M)
AstraZeneca Rare Disease (Alexion) — US product sales: $5,423M in FY2025, up 3.0% from a year earlier.
Where the FY2025 figure comes from
“|| Rare Disease | 9,126 | 5 | 5 | 5,423 | 3 | 1,038 | 22 | 26 | 1,604 | 2 | (1) | 1,061 | 7 | 7”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Therapy Area Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Rare Disease (Alexion) — US product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5,423 | +3.0% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 5,263 | +12.0% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 4,701 | +8.7% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 4,324 | +136.5% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 1,828 | – | Form 6-K FY2021Q4 Earnings Release ↗ |
Breakdown
What makes up rare Disease (Alexion) — US product sales
Cite this data
StockData. (2026). AstraZeneca Rare Disease (Alexion) — US product sales ($M), annual FY2021–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta-rare-us
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.